The pathogenic consequences of a single mutated CFTR gene

Griesenbach, Uta; Geddes, Duncan M.; Alton, Eric W. F. W.
August 1999
Thorax;Aug1999, pS19
Academic Journal
No abstract available.


Related Articles

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype. Clancy, J P; Johnson, S G; Yee, S W; McDonagh, E M; Caudle, K E; Klein, T E; Cannavo, M; Giacomini, K M // Clinical Pharmacology & Therapeutics;Jun2014, Vol. 95 Issue 6, p592 

    Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that...

  • The role of the UPS in cystic fibrosis. Turnbull, Emma L.; Rosser, Meredith F. N.; Cyr, Douglas M. // BMC Biochemistry;2007 Supplement 1, Vol. 8, Special section p1 

    CF is an inherited autosomal recessive disease whose lethality arises from malfunction of CFTR, a single chloride (Cl-) ion channel protein. CF patients harbor mutations in the CFTR gene that lead to misfolding of the resulting CFTR protein, rendering it inactive and mislocalized. Hundreds of...

  • CFTR mutations and polymorphisms in adults with disseminated bronchiectasis: a controversial issue. Divac, A.; Nikolic, A.; Mitic-Milikic, M.; Nagomi-Obrodovic, L.; Petrovic-Stanojevic, N.; Dopudjo-Pantic, V.; Nadoskic, R.; Savic, A.; Rodojkovic, D. // Thorax;Jan2005, Vol. 60 Issue 1, p85 

    Presents a letter to the editor on CFTR gene mutations and polymorphisms in adults with disseminated bronchiectasis.

  • Targeted Therapy for Cystic Fibrosis. Rubenstein, Ronald C. // Molecular Diagnosis & Therapy;Sep2006, Vol. 10 Issue 5, p293 

    Cystic fibrosis (CF) results from the absence or dysfunction of a single protein, the CF transmembrane conductance regulator (CFTR). CFTR plays a critical role in the regulation of ion transport in a number of exocrine epithelia. Improvement or restoration of CFTR function, where it is...

  • Molecular screening of the gene in men with anomalies of the vas deferens: identification of three novel mutations. Jézéquel, Pascal // MHR: Basic Science of Reproductive Medicine;Dec2000, Vol. 6 Issue 12, p1063 

    Investigates the proportion and distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations among males with anomalies of the vas deferens. Identification of mutations in CFTR genes among chromosomes studied; Percentage of patients with detectable CFTR gene...

  • Screening of mutations in the CFTR gene in 1195 couples entering assisted reproduction technique programs. Stuppia, Liborio; Antonucci, Ivana; Binni, Francesco; Brandi, Alessandra; Grifone, Nicoletta; Colosimo, Alessia; De Santo, Mariella; Gatta, Valentina; Gelli, Gianfranco; Guida, Valentina; Majore, Silvia; Calabrese, Giuseppe; Palka, Chiara; Ravani, Anna; Rinaldi, Rosanna; Tiboni, Gian Mario; Ballone, Enzo; Venturoli, Anna; Ferlini, Alessandra; Torrente, Isabella // European Journal of Human Genetics;Aug2005, Vol. 13 Issue 8, p959 

    Genetic testing of the cystic fibrosis transmembrane conductance (CFTR) gene is currently performed in couples undergoing assisted reproduction techniques (ART), because of the high prevalence of healthy carriers in the population and the pathogenic relationship with congenital bilateral absence...

  • Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders — updated European recommendations. Dequeker, Els; Stuhrmann, Manfred; Morris, Michael A.; Casals, Teresa; Castellani, Carlo; Claustres, Mireille; Cuppens, Harry; des Georges, Marie; Ferec, Claude; Macek, Milan; Pignatti, Pier-Franco; Scheffer, Hans; Schwartz, Marianne; Witt, Michal; Schwarz, Martin; Girodon, Emmanuelle // European Journal of Human Genetics;Jan2009, Vol. 17 Issue 1, p51 

    The increasing number of laboratories offering molecular genetic analysis of the CFTR gene and the growing use of commercial kits strengthen the need for an update of previous best practice guidelines (published in 2000). The importance of organizing regional or national laboratory networks, to...

  • Heterogenous spectrum of CFTR gene mutations in Indian patients with congenital absence of vas deferens. N. Sharma; N. Acharya; S.K. Singh; M. Singh; U. Sharma; R. Prasad // Human Reproduction;May2009, Vol. 24 Issue 5, p1229 

    BACKGROUND Mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene can cause congenital bilateral absence of vas deferens. Yet, the spectrum and frequency of CFTR mutations in Indian males with congenital absence of vas deferens (CAVD) is unknown. METHODS We...

  • Improved detection of cystic fibrosis mutations in infertility patients with DNA sequence analysis. Danziger, Kari L.; Black, Lauri D.; Keiles, Steven B.; Kammesheidt, Anja; Turek, Paul J. // Human Reproduction;Vol. 19 Issue 3, p540 

    BACKGROUND: Accurate determination of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is critical for genetic counselling and treatment of obstructive azoospermia. Of concern is that detection rates with routine CFTR mutation panels vary widely depending on...

  • F508del and A561E: cystic fibrosis mutations that disrupt the trafficking, thermostability and gating of CFTR have differential sensitivity to small-molecule CFTR modulators. Wang, Y.; Liu, J.; Gorard, C. V.; Povey, J. N.; Sheppard, D. N.; Li, H. // Proceedings of the Physiological Society;2013, p1P 

    Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. In search of transformational drug therapies for CF patients, small-molecules have been identified that target defects in the expression and function of the commonest CF...


Read the Article


Sign out of this library

Other Topics